Literature DB >> 17184219

Optimization and delivery of plasmid DNA for vaccination.

Wolfgang Jechlinger1.   

Abstract

Vaccination with DNA is one of the most promising novel immunization techniques against a variety of pathogens and tumors, for which conventional vaccination regimens have failed. DNA vaccines are able to stimulate both arms of the immune system simultaneously, without carrying the safety risks associated with live vaccines, therefore representing not only an alternative to conventional vaccines but also significant progress in the prevention and treatment of fatal diseases and infections. However, translation of the excellent results achieved in small animals to similar success in primates or large animals has so far proved to be a major hurdle. Moreover, biosafety issues, such as the removal of antibiotic resistance genes present in plasmid DNA used for vaccination, remain to be addressed adequately. This review describes strategies to improve the design and production of conventional plasmid DNA, including an overview of safety and regulatory issues. It further focuses on novel systems for the optimization of plasmid DNA and the development of diverse plasmid DNA delivery systems for vaccination purposes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17184219     DOI: 10.1586/14760584.5.6.803

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  22 in total

1.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 2.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

Review 3.  Latest developments and future directions in dengue vaccines.

Authors:  Usa Thisyakorn; Chule Thisyakorn
Journal:  Ther Adv Vaccines       Date:  2014-01

4.  Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.

Authors:  Viswa Teja Colluru; Christopher D Zahm; Douglas G McNeel
Journal:  Oncoimmunology       Date:  2016-09-02       Impact factor: 8.110

5.  Construction and gene expression analysis of a single-stranded DNA minivector based on an inverted terminal repeat of adeno-associated virus.

Authors:  Han Ping; Xiaomei Liu; Dongqin Zhu; Taiming Li; Chun Zhang
Journal:  Mol Biotechnol       Date:  2015-04       Impact factor: 2.695

6.  Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia.

Authors:  Maarten A Lijkwan; Alwine A Hellingman; Ernst J Bos; Koen E A van der Bogt; Mei Huang; Nigel G Kooreman; Margreet R de Vries; Hendrika A B Peters; Robert C Robbins; Jaap F Hamming; Paul H A Quax; Joseph C Wu
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

7.  Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA.

Authors:  Renata Bordeira-Carriço; Daniel Ferreira; Denisa D Mateus; Hugo Pinheiro; Ana Paula Pêgo; Manuel A S Santos; Carla Oliveira
Journal:  Eur J Hum Genet       Date:  2014-01-15       Impact factor: 4.246

8.  Novel minicircle vector for gene therapy in murine myocardial infarction.

Authors:  Mei Huang; ZhiYing Chen; Shijun Hu; Fangjun Jia; Zongjin Li; Grant Hoyt; Robert C Robbins; Mark A Kay; Joseph C Wu
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

Review 9.  Harnessing DNA-induced immune responses for improving cancer vaccines.

Authors:  Andrés A Herrada; Nicole Rojas-Colonelli; Paula González-Figueroa; Jonathan Roco; César Oyarce; Maarten A Ligtenberg; Alvaro Lladser
Journal:  Hum Vaccin Immunother       Date:  2012-10-30       Impact factor: 3.452

Review 10.  Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.

Authors:  Saed Abbasi; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.